Relationships Fuel our Growth
Since early 2004, we have been expanding our capabilities through acquisitions and partnerships. These relationships have helped to grow into an advanced diagnostics company focused providing products to enable implementation of the latest advances in patient care and patient management.
Fisher Healthcare
Fisher Healtchare is the exclusive distributor of MGB Alert® real-time PCR products in the United States for the clinical market. In March of 2008, Nanogen expanded its relationship with Fisher Healthcare's parent company, ThermoFisher, through a licensing and distribution agreement. ThermoFisher will use MGB™ real-time PCR technology to market RNA gene expression assays for the research market. www.fishersci.com
ARUP Laboratories
This collaboration agreement with Associated Regional and University Pathologists (ARUP Laboratories), a national reference laboratory, covers the development and supply of Nanogen's MGB™ Detection Reagents. MGB Detection Reagents incorporate Nanogen's proprietary MGB™, Eclipse® Dark Quencher, and modified nucleotide technologies into a real-time PCR detection platform used by clinical diagnostic laboratories to provide information for accurate and timely medical decision making. Under the agreement, ARUP and Nanogen will collaborate on the development and validation of infectious disease assays for use in the clinical diagnostic laboratory. www.aruplab.com.
Gates Foundation Grand Challenge Consortium
The consortium, a collaboration of academic, industry and non-profit partners, was awarded a $15 million grant by the Gates Foundation. The funded project is aimed at developing and testing prototypes of a device about the size of a handheld computer that healthcare workers could pack into remote regions to quickly and easily make life-saving diagnoses.
Celera Diagnostics
In 2004, Nanogen entered into a worldwide non-exclusive license with Celera Diagnostics for incorporation of its MGB™ technology into Celera Diagnostics' products for selected infectious diseases. The license agreement allows Celera Diagnostics to manufacture, sell and distribute TaqMan® probes that utilize Nanogen's minor groove binder and quencher in selected products. Under the agreement, Nanogen receives license fees and royalties on sales of such licensed products to end-users.
In October of 2008, Nanogen expanded its relationship with Celera to develop in vitro diagnostic assays for cardiovascular and oncological applications. This is an expansion of the original license agreement, signed in 2004, in which Celera licensed the technology for development of a hepatitis C genotyping test for individual patient management, monitoring and treatment.
Information about Celera Diagnostics and its infectious disease products is available at www.celeradiagnostics.com